<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of antiretroviral agents used to treat HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of antiretroviral agents used to treat HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of antiretroviral agents used to treat HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney V Fletcher, PharmD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H14340701"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antiretroviral therapy (ART) regimens used to treat individuals with HIV have led to dramatic reductions in morbidity and mortality. Drug selection could potentially include at least 25 antiretroviral medications available in six major classes  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). For most individuals, an ART regimen consists of a dual nucleoside combination plus a third agent from a different class. </p><p>This topic will provide an overview of the different antiretroviral agents used to treat HIV. Topic reviews that discuss the safety of these agents in pregnancy, when to initiate therapy, how to choose a regimen, and antiretroviral resistance are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p></p><p class="headingAnchor" id="H854869005"><span class="h1">OVERVIEW OF HIV REPLICATION</span><span class="headingEndMark"> — </span>The life cycle of HIV can be broken down into 6 steps: (1) entry (binding and fusion), (2) reverse transcription, (3) integration, (4) replication (transcription and translation), (5) assembly, and (6) budding and maturation. The identification and understanding of these processes have provided the basis for antiretroviral drug discovery.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entry</strong> – The process of entry involves the binding of HIV to receptors on the surface of the CD4 cell. Once initial binding occurs, the intimate association of HIV with the cell is enhanced by further binding to chemokine coreceptors, which promotes membrane fusion and internalization of the viral genetic material and enzymes necessary for replication. <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">Maraviroc</a>, <a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">enfuvirtide</a>, and <a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">fostemsavir</a> are antiretroviral agents that inhibit binding and fusion, respectively. However, these agents are not commonly used for the treatment of HIV infection. (See <a class="local">'Entry inhibitors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reverse transcription</strong> – The genetic material of HIV is RNA, and the virus uses reverse transcriptase (one of three virally encoded enzymes: reverse transcriptase, integrase, and protease) to convert its RNA into DNA. Following reverse transcription, the double-stranded viral DNA product migrates into the nucleus of the cell. Nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the process of reverse transcription. There are several agents in each of these classes that are widely used for the treatment of HIV. (See <a class="local">'Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)'</a> below and <a class="local">'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Integration</strong> – The virus uses the enzyme integrase to integrate (insert) its viral DNA into the DNA of the host CD4 cell. Once viral DNA has been integrated into the cell's DNA, the cell is infected for the remainder of its life. Integrase strand transfer inhibitors (INSTIs) inhibit the process of integration. In many countries, INSTIs are considered the preferred third agent (in combination with two nucleoside analogues) for treatment-naïve individuals. (See <a class="local">'Integrase strand transfer inhibitors (INSTIs)'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Replication </strong>– After integration, HIV preferentially replicates in activated cells. Proviral DNA is formed by transcription using the machinery of the host CD4 cell to create new viral RNA. This viral RNA is translated into long polyprotein chains, which will become the protein and enzyme components of new viral particles. There are no antiretroviral agents that inhibit this step of the replication cycle. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assembly</strong> – The new viral proteins and enzymes move to the cell's outer membrane where they assemble into an immature, noninfectious HIV particle or bud. There are no antiretroviral agents that inhibit this step of the replication cycle. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Budding and maturation</strong> – The virus bud is released from the host CD4 cell. The viral enzyme, protease, cuts the long HIV polyprotein chains into smaller functional HIV proteins to make a mature, infectious viral particle. Protease inhibitors are antiretroviral agents that inhibit the HIV protease enzyme, and therefore, prevent this final step in the replication cycle. (See <a class="local">'Protease inhibitors (PIs)'</a> below.)</p><p></p><p class="headingAnchor" id="H1367802175"><span class="h1">CAPSID INHIBITORS</span><span class="headingEndMark"> — </span>Capsid inhibitors are small molecules that disrupt HIV capsid protein functions [<a href="#rid1">1</a>]. This impacts key protein-protein interactions necessary for viral entry and virion assembly. </p><p>in 2022, the capsid inhibitor, <a class="drug drug_general" data-topicid="140392" href="/d/drug information/140392.html" rel="external">lenacapavir</a>, was approved for use in the United States as part of a combination regimen for patients with multi-drug resistant HIV-1 [<a href="#rid2">2</a>]. Patients initiating treatment should receive an initial induction regimen that includes oral lenacapavir, following by subcutaneous injections of lenacapavir every six months. Detailed dosing information can be found in the lenacapavir drug information topic within UpToDate. </p><p>Clinical trials have evaluated <a class="drug drug_general" data-topicid="140392" href="/d/drug information/140392.html" rel="external">lenacapavir</a> in combination with an optimized background ART regimen in 72 patients with multidrug-resistant HIV [<a href="#rid3">3</a>]. Approximately 80 percent achieved a viral load of less than 50 copies/mL by 26 weeks, and none of the patients developed serious adverse events. Thirty-six patients received lenacapavir or placebo in combination with their failing regimen for 15-days prior to receiving open label lenacapavir; a reduction of ≥0.5 log<sub>10</sub> copies/mL in HIV-1 RNA was seen in 88 versus 17 percent of those who received lenacapavir versus placebo, respectively.</p><p class="headingAnchor" id="H1322356540"><span class="h1">ENTRY INHIBITORS</span></p><p class="headingAnchor" id="H1322356567"><span class="h2">CCR5 antagonists</span><span class="headingEndMark"> — </span>HIV enters CD4 cells via the CD4 receptor in conjunction with one of its coreceptors: the chemokine coreceptor 5 (CCR5) or the CXC chemokine coreceptor 4 (CXCR4). Viruses that use the CCR5 coreceptor are called "R5 viruses," whereas others that use the CXCR4 coreceptor are called "X4 viruses." </p><p>Agents that block CCR5 exert their antiviral activity against HIV by blocking entry of CCR5-tropic viruses into the CD4 T cell. <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">Maraviroc</a> is the only approved CCR5 antagonist. Maraviroc is not commonly used for initial treatment of HIV. However, it may have a role in the treatment-experienced patients with drug-resistant virus. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Patients who have failed multiple regimens'</a>.)</p><p>If <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a> is being considered, a tropism assay is essential prior to initiation of therapy. This assay determines whether a response from a CCR5 antagonist should be expected since maraviroc is not active against X4 or dual-mixed tropic viruses. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays", section on 'Tropism assays'</a>.)</p><p><a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">Maraviroc</a> is eliminated by both renal and hepatic pathways. The dose should be adjusted in persons with a creatinine clearance &lt;30 mL/min or on dialysis. Increased maraviroc concentrations are expected in persons with significant hepatic dysfunction, though there are no specific guidelines for dose adjustment. </p><p>In all settings, the dose of <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a> must be adjusted when given with concomitant antiretrovirals (or other drugs) that are CYP3A enzyme inducers (eg, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>) or inhibitors (eg, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>). Refer to the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate for more specific information. </p><p class="headingAnchor" id="H1322356573"><span class="h2">Fusion inhibitors</span><span class="headingEndMark"> — </span>Fusion inhibitors bind to the envelope glycoprotein 41 (gp41) of HIV to prevent viral fusion to the CD4 T cell. The only approved fusion inhibitor is <a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">enfuvirtide</a> (sometimes referred to as T-20), a 36 amino acid peptide. This is an injectable agent that is effective in treatment-experienced patients who have not been exposed to this medication. However, enfuvirtide is difficult to administer for long periods of time due to the need for twice-daily injections, which often lead to local cutaneous reactions. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Fusion inhibitors'</a>.)</p><p class="headingAnchor" id="H1079945660"><span class="h2">Attachment inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">Fostemsavir</a> is an attachment inhibitor that was approved for use in the United States in July 2020 for patients with HIV-1 infection [<a href="#rid4">4</a>]. Fostemsavir is a prodrug, which is converted to the active metabolite temsavir. Temsavir binds directly to the HIV-1 envelope glycoprotein gp120 and prevents viral attachment and subsequent entry of virus into host T cells. </p><p><a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">Fostemsavir</a> is dosed as 600 mg orally twice daily and should be used in combination with other active antiretroviral agents for treatment-experienced patients who are failing therapy and have limited treatment options [<a href="#rid4">4</a>]. It should not be used in patients taking strong cytochrome P450 (CYP)3A inducers (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, St John's wort), as they decrease the level of temsavir. The most common adverse reaction to fostemsavir is nausea. Other adverse reactions include elevations in liver enzymes in those with hepatitis B or C infection, as well as QTc prolongation.</p><p>The efficacy of <a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">fostemsavir</a> was demonstrated in a randomized trial of 272 treatment-experienced patients failing therapy, in which the addition of fostemsavir to a regimen with at least one active agent resulted in a greater reduction of HIV RNA after eight days of treatment compared with a regimen that did not include fostemsavir (0.79 versus 0.17 log<sub>10</sub> copies/mL, respectively) [<a href="#rid5">5</a>]. In this trial, open-label fostemsavir was given to the whole study population after the initial eight days of treatment, and 54 percent achieved an HIV viral load &lt;40 copies/mL at 48 weeks. By 96 weeks, 60 percent of participants had a suppressed viral load [<a href="#rid6">6</a>]. In a separate cohort of 99 patients who had no active drugs but had fostemsavir added to an optimized antiretroviral therapy regimen, 38 percent had an HIV viral load &lt;40 copies/mL at 48 weeks [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1589706004"><span class="h1">NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)</span></p><p class="headingAnchor" id="H1154801468"><span class="h2">NRTI class characteristics</span><span class="headingEndMark"> — </span>The nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) class includes (listed alphabetically)  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">Abacavir</a> sulfate, a guanosine analog. (See <a class="local">'Abacavir'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">Emtricitabine</a> and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, which are cytosine analogs. (See <a class="local">'Emtricitabine and lamivudine'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">Tenofovir alafenamide</a> and <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a>, which are adenosine-derived NRTIs. (See <a class="local">'Tenofovir'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">Zidovudine</a>, a thymidine analog. (See <a class="local">'Zidovudine'</a> below.)</p><p></p><p>Other<strong> </strong>NRTI agents (eg, <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a>) are rarely used because of adverse reactions including neuropathy, lipodystrophy, and mitochondrial toxicity.</p><p>NRTIs are usually given in pairs. The commonly used combinations are available as coformulations (eg, <a class="drug drug_general" data-topicid="107645" href="/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> [Descovy], <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> [Truvada], <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> [Epzicom]). However, two-drug regimens that include an integrase strand transfer inhibitor (INSTI) or a boosted protease inhibitor (PI) in combination with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> can be used in select patients. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Use of two-drug regimens in select patients'</a> and  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – NRTIs undergo intracellular phosphorylation mediated by several host enzymes (eg, cytoplasmic or mitochondrial kinases and phosphotransferases). The active triphosphate form inhibits viral replication through competitive binding to the viral enzyme, reverse transcriptase. DNA chain elongation is terminated after the NRTI triphosphate is incorporated [<a href="#rid7">7,8</a>]. (See <a class="local">'Overview of HIV replication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> – The spectrum of activity of NRTIs includes HIV-1 and HIV-2 viruses. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">Lamivudine</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, and tenofovir (<a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> and <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>) also have activity against hepatitis B virus (HBV). However, lamivudine and emtricitabine should not be used as monotherapy for the treatment of HBV given the high risk of developing HBV resistance with prolonged use. HBV flares can be seen if agents active against HBV are discontinued. A discussion of the treatment of HBV in HIV-infected patients is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – All of the NRTIs can select for resistance mutations. Detailed discussions of HIV drug resistance are found elsewhere. (See  <a class="medical medical_review" href="/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing", section on 'Nucleoside reverse transcriptase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Patients with drug-resistant virus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – The hallmark toxicity of the NRTI class is mitochondrial toxicity, which may manifest as peripheral neuropathy, pancreatitis, lipoatrophy, and/or hepatic steatosis [<a href="#rid9">9-11</a>]. Although all NRTIs have "black box" warnings in their product labeling because of the possibility of lactic acidosis syndrome, which is potentially fatal, the risk of mitochondrial toxicity is low with the commonly used agents (<a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>, <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a>). (See  <a class="medical medical_review" href="/d/html/3765.html" rel="external">"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors"</a>.)</p><p></p><p class="bulletIndent1">Discussions of adverse reactions seen with specific agents are found below. (See <a class="local">'Abacavir'</a> below and <a class="local">'Tenofovir'</a> below and <a class="local">'Zidovudine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – NRTIs have few clinically significant drug-drug interactions because they are not substrates, inhibitors, or inducers of hepatic cytochrome P450 (CYP) enzymes. However, certain important interactions do exist. As an example, <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> should generally be avoided if the patient is receiving a rifamycin (eg, for the treatment of tuberculosis) since rifamycins reduce the level of tenofovir alafenamide [<a href="#rid12">12</a>]. Additional information on drug interactions can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate. </p><p></p><p class="headingAnchor" id="H2698265222"><span class="h2">Specific agents (listed alphabetically)</span></p><p class="headingAnchor" id="H3945320432"><span class="h3">Abacavir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">Abacavir</a> is administered as 300 mg twice daily or as 600 mg once daily. It is also available as part of several coformulated tablets, including <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a>, which is a commonly used NRTI combination, and <a class="drug drug_general" data-topicid="96759" href="/d/drug information/96759.html" rel="external">dolutegravir-abacavir-lamivudine</a>  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). Prior to initiating treatment with abacavir, all patients must be screened for HLA-B*5701. Abacavir is <strong>contraindicated</strong> in persons who test positive for HLA-B*5701, as they are at high risk for developing an abacavir hypersensitivity reaction. (See  <a class="medical medical_review" href="/d/html/3779.html" rel="external">"Abacavir hypersensitivity reaction"</a>.) </p><p>Although <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> is considered a first-line NRTI combination, there are concerns about its use in patients with certain comorbidities, as well as those with high viral loads (unless <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> is used as the third agent). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart disease</strong> – <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">Abacavir</a> should be generally avoided in individuals with coronary artery disease (CAD) as well as those with multiple risk factors for CAD. Although there is no consensus on whether there is a causal association between abacavir and the risk of myocardial infarction, data suggest that abacavir may be associated with an increased risk of hyperlipidemia and cardiovascular events [<a href="#rid13">13-17</a>]. Additionally, in one trial, more favorable changes in the total and low-density lipoprotein (LDL) cholesterol levels were observed among patients who switched from an <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> to a tenofovir disoproxil fumarate-emtricitabine-containing NRTI combination [<a href="#rid18">18</a>]. However, other studies have found no association or only a weak association between abacavir and the risk for myocardial infarction [<a href="#rid15">15,19-21</a>]. Additional information on the use of abacavir in patients with, or at risk for, cardiovascular disease is presented in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Abacavir'</a> and  <a class="medical medical_review" href="/d/html/129782.html" rel="external">"Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral load</strong> – The use of <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> in patients with a high viral load depends upon which third agent is used. As an example, the use of a regimen containing abacavir-lamivudine plus <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> in patients with high viral loads is supported by a randomized, placebo-controlled trial of 833 participants treated with abacavir-lamivudine-dolutegravir versus efavirenz-tenofovir disoproxil fumarate-lamivudine [<a href="#rid22">22</a>]. The abacavir-lamivudine-dolutegravir arm had a significantly greater percentage of participants achieve viral suppression to &lt;50 copies/mL (88 versus 81 percent), and higher CD4 counts (267 versus 208 cells/microL), even among individuals with a baseline HIV RNA &gt;100,000 copies/mL. </p><p></p><p class="bulletIndent1">In contrast, there are conflicting data about the efficacy of <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> in patients with high HIV RNA levels when <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> is not the third agent [<a href="#rid13">13,23,24</a>]. Clinical trial data indicate that patients receiving a nucleoside combination of abacavir-lamivudine are less likely to achieve virologic suppression compared with those receiving <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> when the third drug is <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> or ritonavir-boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> [<a href="#rid13">13</a>]. There are limited data with the use of other third agents in combination with abacavir-lamivudine.</p><p></p><p class="headingAnchor" id="H2610767926"><span class="h3">Emtricitabine and lamivudine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">Emtricitabine</a> and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> are both dideoxycytidine analogues, which have very similar pharmacokinetic and pharmacodynamic characteristics, and are considered interchangeable. Structurally, emtricitabine is very similar to lamivudine, only differing in the addition of a fluorine to emtricitabine. Lamivudine and emtricitabine should <strong>not</strong> be combined because they will compete for intracellular phosphorylation [<a href="#rid25">25</a>]. </p><p>These agents are used as components of the preferred dual NRTI combination (tenofovir-emtricitabine, <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a>). In addition, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> has been used in combination with <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> or a boosted PI in certain treatment-naïve and -experienced patients. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Approach for most patients'</a> and  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Use of two-drug regimens in select patients'</a> and  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.) </p><p>Both <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> are extremely well tolerated. Rare side effects include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatitis – <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">Lamivudine</a> has been associated with pancreatitis, although the risk in adults is quite low at 0.3 percent [<a href="#rid26">26</a>]. The risk of pancreatitis may be higher in children [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin changes – <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">Emtricitabine</a> can cause skin discoloration that presents as hyperpigmentation usually on the palms and/or soles. The incidence appears to be approximately 2 percent [<a href="#rid27">27</a>]. The mechanism and clinical significance is unknown.</p><p></p><p class="headingAnchor" id="H1589706088"><span class="h3">Tenofovir</span><span class="headingEndMark"> — </span>Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate, which is administered orally as the prodrug <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF) or <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF). Both are converted intracellularly to the pharmacologically active moiety, tenofovir-diphosphate. </p><p>TAF is administered at a lower dose than TDF, and plasma concentrations of tenofovir are lower; however, intracellular concentrations of tenofovir-diphosphate are higher. Because of differences in drug transporters involved in TAF versus TDF absorption, there are drug interactions (eg, certain anticonvulsants, rifamycins), which can lower TAF, but not TDF levels. Specific information on drug interactions can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p class="headingAnchor" id="H1145626182"><span class="h4">Tenofovir alafenamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">Tenofovir alafenamide</a> (TAF) is available as part of several coformulated tablets: <a class="drug drug_general" data-topicid="105353" href="/d/drug information/105353.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a> (EVG/c/FTC/TAF), <a class="drug drug_general" data-topicid="107096" href="/d/drug information/107096.html" rel="external">rilpivirine-emtricitabine-tenofovir alafenamide</a> (RPV/FTC/TAF), <a class="drug drug_general" data-topicid="107645" href="/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> (TAF/FTC), <a class="drug drug_general" data-topicid="116731" href="/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a> (BIC/FTC/TAF), and <a class="drug drug_general" data-topicid="118518" href="/d/drug information/118518.html" rel="external">darunavir-cobicistat-emtricitabine-tenofovir alafenamide</a> (DRC/c/FTC/TAF). These coformulated tablets are approved for use in patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m<sup>2</sup>. There are insufficient data for dosing recommendations in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, unless they are on hemodialysis. Special considerations for patients with HIV/HBV coinfection are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV", section on 'Tenofovir in patients with reduced kidney function'</a>.) </p><p>In these coformulated tablets, TAF is used in two different doses: either 10 or 25 mg. When TAF is combined within a pharmacokinetic boosting agent (eg, <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> or <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>) as in <a class="drug drug_general" data-topicid="105353" href="/d/drug information/105353.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a>, the reduced dose of 10 mg is used. When TAF is not given with a pharmacokinetic booster, as in <a class="drug drug_general" data-topicid="107096" href="/d/drug information/107096.html" rel="external">rilpivirine-emtricitabine-tenofovir alafenamide</a> and <a class="drug drug_general" data-topicid="116731" href="/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>, the dose is 25 mg. Pharmacologic boosting agents (eg, cobicistat, ritonavir) inhibit intestinal P-glycoprotein, thereby increasing TAF bioavailability and tenofovir plasma concentrations; the reduced TAF dose of 10 mg is used to manage this interaction. The long-term safety of TAF at the 25 mg dose given with a pharmacokinetic booster has not been established.</p><p>Tenofovir can lead to kidney injury and bone loss; however TAF is associated with less renal and bone toxicity compared with TDF since it achieves lower plasma tenofovir concentrations [<a href="#rid28">28</a>]. In two randomized studies that included 1733 patients, <a class="drug drug_general" data-topicid="105353" href="/d/drug information/105353.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a> was compared with <a class="drug drug_general" data-topicid="86285" href="/d/drug information/86285.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate</a> (EVG/c/FTC/TDF) [<a href="#rid29">29</a>]. More than 90 percent of patients achieved a plasma HIV-RNA &lt;50 copies/mL after 48 weeks, regardless of which agent they received. However, those who received the TAF-containing regimen had significantly smaller increases in serum creatinine (0.08 versus 0.12 mg/dL), less proteinuria (median percent change –3 versus 20), and smaller decreases in bone mineral density (median percent change spine: –1·30 versus –2.86; hip –0.66 versus –2.95).</p><p>Although TAF has several advantages over TDF, TAF may be associated with greater weight gain [<a href="#rid30">30-32</a>]. In addition, levels of LDL and high-density lipoprotein (HDL) cholesterol, as well as triglycerides, have been found to be higher in patients receiving TAF compared with those receiving TDF in randomized trials [<a href="#rid29">29,30</a>]. However, the total cholesterol-to-HDL ratio did not differ between patients receiving TAF and TDF; thus, the clinical significance of these findings is unclear.</p><p class="headingAnchor" id="H1753466820"><span class="h4">Tenofovir disoproxil fumarate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">Tenofovir disoproxil fumarate</a> (TDF) is administered once daily and taken without regard to food. TDF is usually combined with <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> (FTC), which is available as a coformulated tablet (TDF [300 mg]/FTC [200 mg]) [<a href="#rid12">12</a>]. For treatment of HIV infection, <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> must be given with a third agent from a different class, and several combinations of these drugs are available as coformulated tablets  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). There are also generic combination tablets that include TDF, such as TDF (300 mg) with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (300 mg), which are available in resource-limited countries. </p><p>The main toxicities of TDF include kidney injury and bone loss: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney injury</strong> – TDF can lead to renal impairment, characterized by increases in serum creatinine, proteinuria, glycosuria, hypophosphatemia, and acute tubular necrosis [<a href="#rid33">33</a>]. Patterns of kidney injury include proximal tubular dysfunction (Fanconi syndrome), acute kidney injury, chronic kidney disease, and nephrogenic diabetes insipidus [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1">Baseline risk factors for the development of kidney injury from TDF include elevated serum creatinine, older age, advanced HIV infection, low body weight, hepatitis C coinfection, and prescription of concurrent nephrotoxic drugs [<a href="#rid35">35</a>]. Concomitant use with a pharmacokinetically boosted regimen (eg, a protease inhibitor plus <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> plus <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>) may also increase the risk of renal dysfunction [<a href="#rid12">12</a>]. An additional discussion of tenofovir nephrotoxicity is found elsewhere. (See  <a class="medical medical_review" href="/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV", section on 'Medication nephrotoxicity'</a>.)</p><p></p><p class="bulletIndent1">Given the potential for nephrotoxicity:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with HIV, we generally avoid administering TDF to those with a baseline eGFR &lt;60 mL/min/1.73 m<sup>2</sup>. However, if TDF must be used in this setting, the manufacturer recommends the dose be adjusted when the eGFR falls below 50 mL/min/1.73 m<sup>2</sup>. If <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> is used as part of the ART regimen, TDF should not be administered to patients with a pretreatment eGFR &lt;70 mL/min/1.73 m<sup>2</sup>. (See  <a class="medical medical_review" href="/d/html/129782.html" rel="external">"Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions", section on 'Reduced kidney function'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal function and proteinuria should be monitored during the use of this agent. (See  <a class="medical medical_review" href="/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'ART-associated toxicity'</a> and  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis", section on 'Patient monitoring'</a>.)</p><p></p><p class="bulletIndent1">In patients with end-stage kidney disease on hemodialysis in whom recovery of renal function is not anticipated, TDF may be a convenient choice because it can be dosed at 300 mg once weekly (every seven days). (See <a class="local">'Timing of doses for patients on hemodialysis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone loss</strong> – TDF is associated with decreased bone mineral density, which usually stabilizes with continued use [<a href="#rid36">36-38</a>]. In one randomized trial, TDF was associated with a greater reduction in bone mineral density compared with <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a> [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV", section on 'Risk with specific agents'</a>.)</p><p></p><p>Overall, <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> is very well tolerated, and a number of well-designed studies have found that this combination is effective in suppressing HIV RNA when used with a variety of different third agents. Although data are limited, tenofovir disoproxil fumarate-emtricitabine has generally been superior to other nucleoside combinations [<a href="#rid14">14,23,24,27,39-41</a>]. In addition, the combination of tenofovir disoproxil fumarate-emtricitabine has been found to be effective in reducing HIV transmission when administered as pre-exposure prophylaxis (PrEP) to patients without HIV. A detailed discussion of tenofovir disoproxil fumarate-emtricitabine for PrEP is found elsewhere. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p class="headingAnchor" id="H343293595"><span class="h3">Zidovudine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">Zidovudine</a> (also known as AZT) was the first antiretroviral medication used for the treatment of HIV that demonstrated a reduction in the morbidity and mortality associated with HIV infection. Zidovudine is dosed twice daily, as pharmacokinetic and pharmacodynamic studies with once-daily dosing suggest that intracellular trough levels are lower and HIV RNA declines are less robust than with twice-daily dosing [<a href="#rid42">42,43</a>].</p><p class="bulletIndent1">Adverse reactions associated with <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> include headache, malaise, anorexia, nausea, vomiting, lactic acidosis, and loss of limb fat. Administration of zidovudine with food improves gastrointestinal tolerability. The major dose-limiting toxicities of zidovudine are related to bone marrow suppression (eg, anemia and/or neutropenia). </p><p></p><p>The coformulation of <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> (300 mg) and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (150 mg) is dosed as one tablet twice daily. This NRTI combination was a preferred choice when it was first introduced in 1997, but is now rarely used. A tenofovir-containing nucleoside combination or <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> is administered instead of <a class="drug drug_general" data-topicid="10221" href="/d/drug information/10221.html" rel="external">zidovudine-lamivudine</a> for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">Zidovudine</a> requires twice-daily dosing whereas <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a>, <a class="drug drug_general" data-topicid="107645" href="/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a>, and <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> are dosed once daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">Zidovudine</a> is associated with more severe adverse reactions [<a href="#rid40">40,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10221" href="/d/drug information/10221.html" rel="external">Zidovudine-lamivudine</a> has been shown to have inferior virologic potency compared with tenofovir disoproxil fumarate-emtricitabine-based ART [<a href="#rid27">27,40</a>].</p><p></p><p>However, there are certain situations where <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> may still be indicated. As an example, there may be a benefit of using this drug in the setting of the K65R mutation when patients have difficulty achieving viral suppression with more commonly used regimens. In addition, the intravenous formulation of zidovudine (zidovudine is one of the only agents available in a parenteral form) is administered to certain pregnant women at the time of delivery. More detailed discussions of the management of patients with drug-resistant virus and pregnant women are found elsewhere. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Patients who have failed multiple regimens'</a> and  <a class="medical medical_review" href="/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/d/html/126417.html" rel="external">"Intrapartum and postpartum management of pregnant women with HIV and infant prophylaxis in resource-rich settings", section on 'Intrapartum antiretrovirals'</a>.)</p><p class="headingAnchor" id="H1322357618"><span class="h1">NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)</span></p><p class="headingAnchor" id="H3604592045"><span class="h2">NNRTI class characteristics</span><span class="headingEndMark"> — </span>The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are typically administered with a dual nucleoside reverse transcriptase inhibitor (NRTI) combination, although the combination of <a class="drug drug_general" data-topicid="115773" href="/d/drug information/115773.html" rel="external">dolutegravir-rilpivirine</a> is an option for select patients who are virologically suppressed and are switching regimens. (See  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.)</p><p>First-generation NNRTIs include <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>; other NNRTIs (<a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a>, <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a>, and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>) have resistance profiles that are distinct from efavirenz and nevirapine. Most NNRTIs are used for treatment-naïve patients and those with suppressed viral loads switching regimens, except for etravirine, which is generally used for individuals with evidence of drug-resistant virus.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – NNRTIs prevent HIV-1 reverse transcriptase from adding new nucleotides to the growing DNA chain. The NNRTIs block viral cDNA elongation at a site that is separate from the active site targeted by the NRTI class. The NNRTIs bind to a hydrophobic pocket in the palm subdomain of p66, approximately 10 angstroms from the polymerase active site [<a href="#rid45">45</a>]. This causes a stereochemical change in the protein, which reduces the ability of naturally occurring nucleosides to bind to the active site pocket. Reverse transcriptase becomes less flexible and DNA polymerization is inhibited. In addition, cDNA elongation is reduced, which ultimately leads to a decline in viral replication [<a href="#rid46">46</a>]. (See <a class="local">'Overview of HIV replication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> – The NNRTIs are active against HIV-1 but are <strong>not</strong> active against HIV-2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – The first-generation NNRTIs (ie, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>) have a low barrier to resistance and require only a single mutation to confer drug resistance. A major mutation (eg, K103N) leads to cross resistance to other first-generation NNRTIs. In some cases, the second-generation NNRTI, <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a>, can be used in the treatment of patients with resistance to first-generation NNRTIs [<a href="#rid12">12,47</a>]. Virologic failure on <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> may also compromise the anti-HIV activity of other NNRTIs, including etravirine. (See  <a class="medical medical_review" href="/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing", section on 'Non-nucleoside reverse transcriptase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'NNRTI-containing regimens'</a>.)</p><p></p><p class="bulletIndent1">Oral NNRTIs have a long plasma half-life, typically &gt;24 hours in adults, with the exception of <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a>, which has a half-life of 15 to 21 hours. The long half-life allows all NNRTIs to be administered once daily. Importantly, when an NNRTI-containing antiretroviral regimen is discontinued, a period of functional NNRTI monotherapy may occur if the concentrations of the NNRTI decline slower than those of the other antiretrovirals. This period of functional monotherapy or "NNRTI tail" increases the risk of developing NNRTI resistance [<a href="#rid48">48,49</a>]. Thus, some experts suggest that if a regimen containing an NNRTI is stopped, the concomitant nucleoside backbone should be continued for three to seven days after the NNRTI is discontinued. An alternative strategy is for a boosted protease inhibitor to be substituted for the NNRTI for one week before discontinuing the nucleoside backbone. These relatively cumbersome stop strategies have not been well studied, and it is difficult to recommend any one approach. Specific considerations regarding the injectable formulation are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Drug interactions can result in increased or decreased NNRTI levels, and NNRTIs may be a perpetrator of drug interactions. Detailed information about specific interactions is available by using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – There are no specific class-related adverse events. However, the two most commonly used NNRTIs (<a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>) can result in neurologic and psychiatric side effects. They are also associated with QT prolongation.</p><p></p><p class="headingAnchor" id="H3096422761"><span class="h2">Specific agents (listed alphabetically)</span></p><p class="headingAnchor" id="H2008319289"><span class="h3">Doravirine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">Doravirine</a> became available in the United States in August of 2018. This agent is approved for use in treatment-naïve patients and is available alone or in combination with tenofovir disoproxil fumarate-lamivudine. Doravirine may be administered with or without food, and there are no viral load or CD4 count parameters to initiate therapy. </p><p><a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">Doravirine</a> is metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect plasma concentrations. As an example, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> decreases doravirine exposure by &gt;70 percent, and coadministration is contraindicated. By contrast, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> decreases doravirine exposure by 50 percent, and this interaction may be managed by increasing the doravirine dose from 100 mg once daily to 100 mg twice daily. Detailed information about specific interactions is available by using the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate. </p><p><a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">Doravirine</a> was found to be non-inferior to efavirenz- and darunavir-based regimens in randomized trials [<a href="#rid50">50,51</a>]. In addition, it appears to be well tolerated. Although it may cause neurologic and psychiatric side effects similar to <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> (eg, dizziness, sleep disturbances, and altered sensorium), these are much less common. In the trial that compared doravirine-lamivudine- <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> with <a class="drug drug_general" data-topicid="8858" href="/d/drug information/8858.html" rel="external">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a>, the rates of neuropsychiatric adverse events at 48 weeks were 12 versus 22 percent, respectively [<a href="#rid50">50</a>]. Clinical trial data also suggest that it has better lipid profiles than both efavirenz and <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> [<a href="#rid50">50,51</a>]. Additional information on the adverse events associated with efavirenz and darunavir are presented elsewhere. (See <a class="local">'Efavirenz'</a> below and <a class="local">'Darunavir'</a> below.)</p><p>Despite the favorable clinical trial data, there is limited experience with this agent, and <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> has never been directly compared with integrase strand transfer inhibitors (INSTIs), the preferred third agent for most patients. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Approach for most patients'</a>.) </p><p class="headingAnchor" id="H1322357772"><span class="h3">Efavirenz</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">Efavirenz</a> is given at a dose of 600 mg once daily. It is also available as part of coformulated tablets (<a class="drug drug_general" data-topicid="8858" href="/d/drug information/8858.html" rel="external">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a> and <a class="drug drug_general" data-topicid="116732" href="/d/drug information/116732.html" rel="external">efavirenz-lamivudine-tenofovir disoproxil fumarate</a>)  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). Since efavirenz is a potent inducer of hepatic cytochrome P450 (CYP) enzymes, drug interactions can be seen with certain medications that are commonly used in patients with HIV. These include <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and other anticonvulsants. Detailed information about specific interactions is available by using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p><a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">Efavirenz</a> has been used extensively and has excellent potency and durability in treatment-naïve patients, including those with high pretreatment viral loads and low CD4 cell counts [<a href="#rid11">11,27,52-59</a>]. However, INSTIs are preferred, due in part to fewer adverse events [<a href="#rid12">12,22,60-63</a>]. (See <a class="local">'Integrase strand transfer inhibitors (INSTIs)'</a> below.)</p><p>Side effects seen with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> include central nervous system (CNS) toxicity, elevated hepatic transaminases (including fulminant hepatitis), and QT interval prolongation. Thus, this agent is typically avoided in patients with psychiatric illness, moderate to severe liver disease (Child Pugh B and C), and those at risk for torsade de pointes. Other side effects include rash and hyperlipidemia. The safety of efavirenz during pregnancy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy", section on 'Efavirenz'</a>.) </p><p>The CNS symptoms, which are one of the most frequently seen side effects, commonly include vivid dreams, confusion, dizziness, and a "hungover" feeling the following day. Higher rates of intolerance are noted in Black patients due to slower metabolism that is genetically determined. Taking <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> on an empty stomach may reduce the risk of these side effects since high-fat/high-caloric meals increase the absorption of efavirenz.</p><p>Although many CNS side effects are restricted to the first few weeks after initiation, there are data that suggest long-term mental health consequences (eg, irritability, anxiety, mood changes, depression) and increased suicidality (combined endpoint of suicidal ideation, suicide attempts, and completed suicides) can be seen with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> [<a href="#rid64">64-67</a>]. A combined analysis of 5332 HIV-infected individuals from four clinical trials evaluated the risk of suicidality among those receiving an efavirenz-containing regimen [<a href="#rid66">66</a>]. There was a significantly increased incidence of suicidality among those who received efavirenz compared with those who did not (8.08 versus 3.66 per 1000 person-years; hazard ratio 2.28; 95% CI, 1.27-4.10). The increased risk of suicidality appears to be greatest in patients who have genotypes that predict higher plasma efavirenz exposure [<a href="#rid68">68</a>]. This may help explain why an increase in suicidality is not seen in all patient groups [<a href="#rid69">69</a>]. </p><p>A fixed-dose combination of tenofovir disoproxil fumarate-lamivudine-efavirenz using a lower dose of <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> (400 mg) is available. Clinical trial data in antiretroviral-naïve persons suggest that this lower dose of efavirenz is noninferior to the 600 mg dose with regards to virologic efficacy [<a href="#rid70">70,71</a>] and may be associated with fewer adverse events [<a href="#rid70">70</a>]. In one study, the 400 mg dose of efavirenz appeared to be noninferior to <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> at 48 weeks, with 69 and 75 percent of patients achieving a viral load &lt;50 copies, respectively [<a href="#rid72">72</a>]. However, the 400 mg dose of efavirenz is not routinely used in clinical practice.</p><p class="headingAnchor" id="H1267041590"><span class="h3">Etravirine</span><span class="headingEndMark"> — </span>The most commonly used NNRTI for patients with drug-resistant virus is <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> [<a href="#rid73">73</a>]. The likelihood that etravirine will be active against a particular virus can be determined via a weighted mutation score based upon the specific NNRTI mutations  (<a class="graphic graphic_table graphicRef55515" href="/d/graphic/55515.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing", section on 'Non-nucleoside reverse transcriptase inhibitors'</a>.)</p><p>If <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> is part of the new regimen, it should be used with at least one, and ideally two, other fully active drugs; if this is not possible, it should be used with multiple partially active agents. Increasing the number of active antiretroviral agents used in combination with etravirine increases the likelihood of obtaining the desired treatment response [<a href="#rid18">18,19</a>]. As an example, in a study of 243 patients with multidrug resistance, the use of two or more active agents in combination with etravirine increased the likelihood of achieving HIV RNA suppression by more than eightfold [<a href="#rid19">19</a>]. </p><p>The most common adverse event after <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> administration is rash, which is generally mild. In clinical trials, rash occurred primarily in the second week of therapy and was infrequent after week four. Rash generally resolved within one to two weeks of continued dosing. As with other NNRTIs, severe rashes (including Stevens-Johnson Syndrome, toxic epidermal necrolysis, and erythema multiforme) have been reported in the postmarketing experience. Etravirine should be immediately discontinued when signs and symptoms of severe skin or hypersensitivity reactions develop. </p><p>There are significant drug-drug interactions with <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> and other antiretroviral medications that can limit its use. As an example, if etravirine is used with <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, the regimen must also include a boosted PI. A detailed review of drug interactions can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p class="headingAnchor" id="H2602594915"><span class="h3">Nevirapine</span><span class="headingEndMark"> — </span>In the United States, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> is no longer recommended for the initial treatment of HIV infection in treatment-naïve patients [<a href="#rid12">12,63</a>]. Compared with other NNRTIs, nevirapine is associated with increased toxicity, especially during the first three months of therapy. Complications include hepatic necrosis and serious cutaneous reactions, including deaths due to hepatic necrosis or Stevens-Johnson Syndrome [<a href="#rid74">74-81</a>].</p><p>If <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> is being considered, it should <strong>not</strong> be initiated in females with a baseline CD4 count &gt;250 cells/microL or in males with a CD4 count &gt;400 cells/microL since these CD4 cell thresholds represent major risk factors for hepatotoxicity. Caution should also be used when nevirapine is initiated in males with CD4 cell counts between 250 to 400 cells/microL. A study of 566 patients from China showed that a CD4 cell count of &gt;250 cells/microL was an independent predictor of hepatotoxicity in both males and females initiated on a nevirapine-containing regimen [<a href="#rid82">82</a>]. </p><p><a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">Nevirapine</a> should also be avoided in patients with moderate to severe liver disease (Child-Pugh Class B or C) (<a class="calc calc_professional" href="/d/html/15639.html" rel="external">calculator 1</a>). As described above, nevirapine has been associated with hepatotoxicity, and data on its use in this population are limited. </p><p>If administered, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> should be started at a dose of 200 mg once daily for 14 days; the dose is then increased to the maintenance dose of 200 mg twice daily. We monitor serum aminotransferases at baseline, prior to and two weeks after dose escalation, then monthly for the first three months. Patients should also be counseled about symptoms and signs of hepatotoxicity (eg, nausea, jaundice). </p><p class="headingAnchor" id="H1322358346"><span class="h3">Rilpivirine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">Rilpivirine</a> is formulated both as an individual tablet (25 mg once daily) and in three fixed-dose combination tablets (<a class="drug drug_general" data-topicid="16793" href="/d/drug information/16793.html" rel="external">rilpivirine-emtricitabine-tenofovir disoproxil fumarate</a>, <a class="drug drug_general" data-topicid="107096" href="/d/drug information/107096.html" rel="external">rilpivirine-emtricitabine-tenofovir alafenamide</a>, and <a class="drug drug_general" data-topicid="115773" href="/d/drug information/115773.html" rel="external">dolutegravir-rilpivirine</a>), all of which can be administered once daily  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). It is also available in an injectable formulation that must be used with <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a>. (See <a class="local">'Cabotegravir'</a> below.)</p><p><a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">Rilpivirine</a> can be used in combination with tenofovir-emtricitabine in treatment-naïve patients with a baseline viral load &lt;100,000 copies/mL and a CD4 cell count ≥200 cells/microL [<a href="#rid12">12</a>]. This combination, as well as the two-drug combination of <a class="drug drug_general" data-topicid="115773" href="/d/drug information/115773.html" rel="external">dolutegravir-rilpivirine</a>, can also be used in select virologically suppressed patients who are switching regimens. (See  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.)</p><p><a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">Rilpivirine</a> should be used cautiously or avoided in patients with long QT syndrome or other risks for torsade de pointes [<a href="#rid12">12</a>]. High doses of rilpivirine (ie, 75 mg and 300 mg once daily) were associated with QT interval prolongation [<a href="#rid83">83</a>].</p><p>Gastric acid and food are required for optimal absorption; thus, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> must be administered with a meal, and concomitant use of rilpivirine with proton pump inhibitors is contraindicated. In addition, other drugs that alter the stomach pH (eg, H2 antagonists, antacids) may impair absorption and should be avoided if possible; however, if they are used, they should be dosed separately from rilpivirine.</p><p>Important drug interactions can also be seen with certain anti-tuberculosis medications (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>), anti-epileptics (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>), and drugs that may inhibit <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> metabolism and increase plasma concentrations (eg, azole antifungals, macrolide antibiotics). Detailed information about specific interactions is available by using the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p><a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">Rilpivirine</a> is generally well tolerated [<a href="#rid84">84</a>]. The most common adverse drug reactions to rilpivirine include depression, insomnia, headache, and rash. Although rilpivirine may cause neurologic and psychiatric side effects similar to <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, they are much less common [<a href="#rid85">85</a>]. In addition, rash led to drug discontinuation in less than 1 percent of study participants in the phase 3 clinical trials [<a href="#rid86">86</a>]. </p><p>Two controlled trials (ECHO and THRIVE) compared <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> in treatment-naïve patients in combination with two NRTIs; most received <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> as the NRTI combination [<a href="#rid87">87-89</a>]. The pooled results demonstrated that the proportion of patients with viral suppression at 48 weeks was comparable in the rilpivirine and efavirenz-containing arms. Rilpivirine was also well tolerated and associated with minimal changes in lipids. </p><p>In a 96-week analysis of 1368 participants, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> had a lower incidence of any neurologic or psychiatric adverse event compared with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> (38 versus 17 percent and 24 versus 16 percent, respectively) [<a href="#rid88">88</a>]. However, among those subjects with a baseline viral load &gt;100,000 copies/mL, the risk of virologic failure was higher in the rilpivirine arm compared with the efavirenz arm. An increased risk of nucleoside analog resistance mutations (eg, M184V/I) was also noted in these trials [<a href="#rid87">87-89</a>]. </p><p>The combination of <a class="drug drug_general" data-topicid="107096" href="/d/drug information/107096.html" rel="external">rilpivirine-emtricitabine-tenofovir alafenamide</a> was approved on the basis of pharmacokinetic bioequivalence; comparative clinical trial data have not yet been reported.</p><p class="headingAnchor" id="H1322359788"><span class="h1">INTEGRASE STRAND TRANSFER INHIBITORS (INSTIs)</span></p><p class="headingAnchor" id="H3041301799"><span class="h2">INSTI class characteristics</span><span class="headingEndMark"> — </span>Regimens using integrase strand transfer inhibitors (INSTIs), such as <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, and bictegravir, are effective and well tolerated. Most INSTIs are administered orally. An injectable, long-acting INSTI (<a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a>) is also available for treatment and must be used in combination with injectable <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>. (See  <a class="medical medical_review" href="/d/html/138435.html" rel="external">"Use of long-acting cabotegravir-rilpivirine in people with HIV"</a>.)</p><p>In many countries, including the United States, INSTIs are considered the preferred third agent for treatment-naïve individuals when used in combination with two nucleoside analogues. These agents are a particularly attractive option for patients with either abnormal lipid profiles or risk factors for coronary artery disease, since they have a neutral effect on cholesterol and triglycerides compared with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and protease inhibitors. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – HIV integrase is one of three enzymes (reverse transcriptase, protease, and integrase) that are encoded by the virus and are essential for HIV replication. After entry into CD4+ T cells, viral RNA is reverse transcribed into DNA by HIV reverse transcriptase. The integrase enzyme catalyzes the process by which viral DNA is integrated into the genome of the host cell. This process is essential for maintenance of the viral genome and viral gene expression [<a href="#rid90">90-95</a>].</p><p></p><p class="bulletIndent1">Integrase inhibitors target the strand transfer step of viral DNA integration. These drugs prevent or inhibit the binding of the preintegration complex (PIC) to host cell DNA, thus terminating the integration step of HIV replication. (See <a class="local">'Overview of HIV replication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> – The integrase inhibitors are active against HIV-1 and HIV-2. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – HIV-infected patients who fail an antiretroviral therapy (ART) regimen that contains <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> or <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> have a relatively high risk of developing integrase resistance. In addition, there appears to be a high level of cross resistance between raltegravir and elvitegravir, precluding their sequential use [<a href="#rid96">96-98</a>]. As an example, in one study, 13 of the 23 patients who experienced virologic failure while receiving elvitegravir developed the following drug resistance mutations: T66I, E92Q, Q148R, and N155H [<a href="#rid99">99</a>]; three of these mutations (E92Q, Q148R, and N155H) also conferred significant resistance to raltegravir. </p><p></p><p class="bulletIndent1">By contrast, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> and bictegravir resistance is very uncommon among patients failing an initial regimen that contains one of these agents [<a href="#rid100">100,101</a>]. It is also uncommon for such individuals to develop resistance to the NRTIs that are administered in combination with dolutegravir or bictegravir. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – A decrease in INSTI concentrations is possible when administered with polyvalent cation-containing antacids and supplements. With regards to specific agents, there are relatively few problematic drug-drug interactions with <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> and <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> because they are primarily metabolized via glucuronidation. Bictegravir, which is cleared by both glucuronidation and hepatic cytochrome P450, also has few problematic drug interactions. By contrast, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> is associated with more drug-drug interactions since it is administered with the boosting agent <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>, which is a potent inhibitor of CYP3A. More specific information on drug-drug interactions is found in the sections below and in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – All INSTIs are generally well tolerated. However, INSTIs may be associated with increased weight gain compared with other agents [<a href="#rid32">32,72,102-104</a>]. In one study that evaluated data from eight randomized trials, weight gain at 96 weeks was approximately 3.5 kg, and was similar in those that received bictegravir- and dolutegravir-based regimens. The mechanism for this weight gain is not known. </p><p></p><p class="bulletIndent1">Insomnia and dizziness can also occur in some patients receiving INSTIs [<a href="#rid105">105,106</a>]. In addition, depression and suicidal ideation have been reported on rare occasion, primarily in patients with a history of psychiatric illnesses [<a href="#rid12">12</a>]. On occasion, elevations in creatine phosphokinase (CPK), rhabdomyolysis, and myopathy or myositis have been reported in patients taking <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> and <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations in persons of childbearing potential and those who are pregnant</strong> – When deciding whether to use a regimen that includes an INSTI in individuals who are of childbearing potential, it is important to determine if the person is pregnant and, if not, if they are committed to using effective birth control (eg, oral, injectable, or intrauterine contraception). Pregnancy, as well as the desire to become pregnant, may impact the selection of ART agents used for treatment of HIV infection. Detailed discussions of the use of INSTIs in persons who are of childbearing potential and in those who are pregnant are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3753.html" rel="external">"HIV and women"</a> and  <a class="medical medical_review" href="/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings", section on 'ART selection and management'</a> and  <a class="medical medical_review" href="/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a>.)</p><p></p><p class="headingAnchor" id="H1996606489"><span class="h2">Specific agents (listed alphabetically)</span></p><p class="headingAnchor" id="H631829738"><span class="h3">Bictegravir</span><span class="headingEndMark"> — </span>Bictegravir was approved for use in February 2018 and is available as a coformulated tablet with <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> and <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>. It has been approved for use in treatment-naïve patients and in those who are virologically suppressed and are considering a change in their regimen. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"</a>.)</p><p>There are limited data using this drug in treatment-experienced patients with a history of virologic failure. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p>Overall, <a class="drug drug_general" data-topicid="116731" href="/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a> appears well tolerated. Notable drug interactions include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="8904" href="/d/drug information/8904.html" rel="external">dofetilide</a>, which are contraindicated for coadministration with bictegravir. </p><p><a class="drug drug_general" data-topicid="116731" href="/d/drug information/116731.html" rel="external">Bictegravir-emtricitabine-tenofovir alafenamide</a> can be used in patients on hemodialysis; it is approved for use in treatment-experienced patients who are virologically suppressed. Similar to most other antiretroviral agents, it has not been evaluated in treatment-naïve patients on hemodialysis.</p><p class="headingAnchor" id="H3441393515"><span class="h3">Cabotegravir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">Cabotegravir</a> is available as an oral and injectable preparation, which must be used in conjunction with <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> for treatment of HIV [<a href="#rid12">12,63</a>]. The oral formulation is only approved for use as lead-in therapy prior to initiating injectable therapy or for patients who will miss planned injections of cabotegravir. Injectable <a class="drug drug_general" data-topicid="130321" href="/d/drug information/130321.html" rel="external">cabotegravir-rilpivirine</a> should only be used in treatment-experienced patients who are virologically suppressed, have no resistance to either drug, do not have chronic hepatitis B infection, have no significant drug-drug interactions that might reduce either drug's concentration, and are able to adhere to clinic visits for intramuscular injections. (See  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a> and  <a class="medical medical_review" href="/d/html/138435.html" rel="external">"Use of long-acting cabotegravir-rilpivirine in people with HIV", section on 'Determining eligibility'</a>.)</p><p>The injectable regimen is administered every four or eight weeks. Overall, <a class="drug drug_general" data-topicid="130321" href="/d/drug information/130321.html" rel="external">cabotegravir-rilpivirine</a> is well tolerated; however, when the injectable formulation is used, mild to moderate injection site reactions are common. The most common other adverse reactions are mild and nonspecific, such as pyrexia, fatigue, headache, muscle aches, nausea, sleep disorders, dizziness, and rash. On rare occasion, serious post-injection reactions due to <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> have been reported (dyspnea, flushing, sweating); however, these typically resolve within minutes.</p><p>Some drugs are contraindicated for coadministration with intramuscular <a class="drug drug_general" data-topicid="130321" href="/d/drug information/130321.html" rel="external">cabotegravir-rilpivirine</a>, such as the rifamycins (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>) and certain anticonvulsants (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>). Information on specific drug-drug interactions can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate. </p><p>A more detailed discussion of <a class="drug drug_general" data-topicid="130321" href="/d/drug information/130321.html" rel="external">cabotegravir-rilpivirine</a>, including dosing regimens, the approach to missed doses, and the data supporting its efficacy, is presented in the Lexicomp drug information topic and in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a> and  <a class="medical medical_review" href="/d/html/138435.html" rel="external">"Use of long-acting cabotegravir-rilpivirine in people with HIV"</a>.)</p><p class="headingAnchor" id="H3905625084"><span class="h3">Dolutegravir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">Dolutegravir</a> is approved for use in treatment-naïve and most treatment-experienced individuals [<a href="#rid107">107</a>]. Patients receiving dolutegravir are unlikely to develop drug-resistant virus [<a href="#rid108">108</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>For most patients, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> is given at a dose of 50 mg once daily without regard to food. It can be administered with a tenofovir-containing nucleoside combination or <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a>. Topic reviews that discuss regimen selection are presented separately. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">Dolutegravir</a> is available as part of three coformulated tablets (<a class="drug drug_general" data-topicid="96759" href="/d/drug information/96759.html" rel="external">dolutegravir-abacavir-lamivudine</a>, <a class="drug drug_general" data-topicid="120975" href="/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a>, and <a class="drug drug_general" data-topicid="115773" href="/d/drug information/115773.html" rel="external">dolutegravir-rilpivirine</a>)  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="115773" href="/d/drug information/115773.html" rel="external">Dolutegravir-rilpivirine</a> is only approved for use in virologically suppressed individuals switching regimens. Detailed discussions of the use of these regimens, including contraindications to their use, are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose of <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> should be increased to 50 mg twice daily for treatment-experienced patients who have previously taken integrase inhibitors and have confirmed or suspected integrase resistance. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Patients with drug-resistant virus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">Dolutegravir</a> should <strong>not</strong> be used for patients who have the Q148 mutation in addition to two or more secondary integrase mutations, since such patients respond less well to a dolutegravir-containing regimen [<a href="#rid109">109-111</a>]. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Integrase strand transfer inhibitors'</a>.)</p><p></p><p></p><p><a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">Dolutegravir</a> can block tubular secretion of creatinine without reducing renal glomerular function. In some patients, this can lead to an expected small increase in serum creatinine (and decrease in eGFR) [<a href="#rid101">101</a>].</p><p>Several trials have shown that <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> is well tolerated [<a href="#rid22">22,112,113</a>]. However, dolutegravir may be associated with more central nervous side effects (CNS) compared with other INSTIs [<a href="#rid105">105</a>]. This was demonstrated in a retrospective review of 1704 patients taking 1950 INSTI-based therapies, where neuropsychiatric adverse events (eg, insomnia and dizziness) resulted in treatment discontinuation more frequently in those receiving dolutegravir versus a different INSTI (5.6 percent for dolutegravir versus 0.7 and 1.9 percent for <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> and <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, respectively). These CNS side effects occurred significantly more frequently in females, and in patients older than 60 years.</p><p><a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">Dolutegravir</a> can have significant interactions with agents, such as <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and antiepileptics (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>). Detailed information can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p>There are no clinically significant drug interactions between <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> and NRTIs or the boosted protease inhibitors <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> and lopinavir. This is because dolutegravir does not induce or inhibit CYP or UGT isoenzymes at clinically relevant concentrations [<a href="#rid114">114</a>]. Although dolutegravir trough concentrations are reduced by approximately 38 percent when given with <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, this is not considered clinically significant. In addition, it appears there is not a clinically significant adverse interaction if dolutegravir is given with darunavir/<a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> [<a href="#rid115">115</a>]. However, there are very limited data assessing possible interactions between dolutegravir and cobicistat. </p><p>The concentration of <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> can be affected when dolutegravir is administered with drugs that inhibit or induce the UGT family of enzymes and CYP3A4. As an example, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> reduce dolutegravir trough concentrations by 75 and 88 percent, respectively. Dose adjustments or coadministration with a ritonavir-boosted protease inhibitor are required when these agents are used together; specific recommendations can be found at the United States Department of Health and Human Services (DHHS) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fadult-and-adolescent-arv%2Fdrug-interactions-between-integrase-inhibitors-and-other-drugs%3Fview%3Dfull&amp;token=E6bSi1B9DZqB6AmLjfC%2BU%2BzqFQ7m3PVQsvg3iH5uI4ge9HRUldnyTyeYl49fPNrrUEdzwM6oLAJ%2B3%2FnrMMBzKPbyB6emGSEREy4mWiWxkNT362p%2FE0LOMXwy2Wpg4RXHG81Wq3PNJrKEdu8ZoPzXMQ%3D%3D&amp;TOPIC_ID=13978">Antiretroviral Guidelines for Adults and Adolescents</a>. </p><p>Clinical trial data supporting the efficacy of <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span>Studies of <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> have used both <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> and <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> as nucleoside backbone therapy [<a href="#rid112">112</a>]. The virologic response rates were comparable to those seen in patients treated with <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, even among patients with baseline HIV RNA &gt;100,000 copies/mL, and there were no differences in the rates of discontinuation for adverse events. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At 48 weeks, <a class="drug drug_general" data-topicid="96759" href="/d/drug information/96759.html" rel="external">dolutegravir-abacavir-lamivudine</a> was associated with significantly more frequent viral suppression to &lt;50 copies/mL (88 versus 81 percent) and higher CD4 counts (267 versus 208 cells/microL) when compared with <a class="drug drug_general" data-topicid="8858" href="/d/drug information/8858.html" rel="external">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a> [<a href="#rid22">22</a>]. This was seen even among individuals with a baseline HIV RNA &gt;100,000 copies/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> were more likely to have an HIV RNA level &lt;50 copies/mL (90 versus 83 percent) compared with <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> (800/100 mg once daily) in an open-label, randomized clinical trial [<a href="#rid116">116</a>]. This difference was greatest in those with a baseline HIV RNA &gt;100,000 copies/mL. </p><p></p><p class="headingAnchor" id="H146559118"><span class="h3">Elvitegravir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">Elvitegravir</a> can be used for treatment-naïve or treatment-experienced patients. However, it must be administered with a boosting agent (eg, <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> or <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>), which is a potent inhibitor of CYP3A and thus causes more potential drug-drug interactions. A discussion of pharmacokinetic boosting is found below. (See <a class="local">'Pharmacokinetic boosting'</a> below.) </p><p><a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">Elvitegravir</a> was initially approved for use in treatment-naïve HIV-infected patients as part of a fixed-dose antiretroviral combination, <a class="drug drug_general" data-topicid="86285" href="/d/drug information/86285.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate</a> (EVG/c/FTC/TDF). This combination can be administered once daily, but only to patients with a pre-treatment eGFR &gt;70 mL/min/1.73 m<sup>2</sup>. In November 2015, the coformulation of <a class="drug drug_general" data-topicid="105353" href="/d/drug information/105353.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a> (EVG/c/FTC/TAF) became available for treatment-naïve patients. Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide can be administered to patients with reduced kidney function who have an eGFR ≥30 mL/min/m<sup>2</sup>.</p><p><a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">Elvitegravir</a>, like <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, has a low genetic barrier to resistance. In addition, drug-drug interactions should be thoroughly assessed as it must be administered with a pharmacologic boosting agent. (See <a class="local">'Pharmacokinetic boosting'</a> below.)</p><p>Clinical trials supporting the use of <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> include:</p><p class="bulletIndent1"><span class="glyph">●</span>Two trials that enrolled 1408 treatment-naïve patients with a pre-treatment eGFR &gt;70 mL/min/1.73 m<sup>2</sup> found that <a class="drug drug_general" data-topicid="86285" href="/d/drug information/86285.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate</a> was noninferior to coformulated <a class="drug drug_general" data-topicid="8858" href="/d/drug information/8858.html" rel="external">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a> or ritonavir-boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> plus <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> in achieving viral suppression at 48 weeks of therapy [<a href="#rid60">60,117</a>]. The most common adverse events on the <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> regimen were headache and transient diarrhea and nausea; four patients developed proximal tubulopathy in these phase 3 clinical trials. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trials have shown <a class="drug drug_general" data-topicid="105353" href="/d/drug information/105353.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a> has equal efficacy and less nephrotoxicity and bone loss compared with <a class="drug drug_general" data-topicid="86285" href="/d/drug information/86285.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate</a> [<a href="#rid29">29,118</a>]. In addition, patients who are virologically suppressed on a tenofovir disoproxil fumarate-containing regimen were able to safely switch to elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide. In an open-label, randomized trial of 1443 patients who were virologically suppressed on a regimen containing <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> for 96 weeks, patients were switched to elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide or were continued on their regimen [<a href="#rid118">118</a>]. By 48 weeks, the tenofovir alafenamide-containing regimen was found to be noninferior to a tenofovir disoproxil fumarate-containing regimen, and 97 percent of the 959 patients who were assigned to elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide had an HIV RNA &lt;50 copies/mL.</p><p></p><p class="headingAnchor" id="H1589708487"><span class="h3">Raltegravir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">Raltegravir</a> is approved for use in treatment-naïve and treatment-experienced patients with HIV as part of a combination ART regimen [<a href="#rid61">61,62,119-121</a>]. It is available in 400 mg and 600 mg tablets. A discussion of how to select an ART regimen is presented separately. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p><a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">Raltegravir</a> is generally administered as 400 mg twice daily (800 mg total daily dose). However, once daily dosing with two 600 mg tablets (1200 mg total daily dose) is an option for patients who are treatment naïve or who are virologically suppressed (eg, HIV RNA &lt;50 copies/mL) on an initial regimen of raltegravir 400 mg twice daily. If raltegravir is coadministered with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, it should be administered as 800 mg twice daily (1600 mg total daily dose) regardless of prior ART experience. </p><p>Although rare, side effects can be seen with <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, and include nausea, dizziness, and headache. Rare cases of skeletal muscle toxicity and severe systemic cutaneous reaction resembling Stevens-Johnson syndrome have also been reported [<a href="#rid122">122-124</a>]. </p><p>As with other INSTIs, clinical trial data have found that <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, when used in combination with <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a>, is among the most effective agents in suppressing the HIV viral load. Raltegravir has demonstrated superior viral suppression compared with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> [<a href="#rid61">61,62</a>] and was found to be superior to first-line protease inhibitors (ie, boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> and boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>) when combined tolerability and virologic efficacy endpoints were evaluated [<a href="#rid125">125</a>]. In addition, raltegravir achieves meaningful drug concentrations in cerebral spinal fluid and genital compartments [<a href="#rid126">126,127</a>]. </p><p>One of the main disadvantages of <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> is its lower genetic barrier to resistance compared with <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> and protease inhibitors (N155H is its signature mutation) [<a href="#rid100">100,125</a>]. As an example, in one study virologic resistance developed in 3 percent of patients receiving raltegravir versus ≤1.5 percent in those receiving a protease inhibitor [<a href="#rid125">125</a>]. In addition, raltegravir has been studied only in combination with <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> as the NRTI pair.</p><p class="headingAnchor" id="H1322359219"><span class="h1">PROTEASE INHIBITORS (PIs)</span><span class="headingEndMark"> — </span>Protease inhibitors (PIs) are typically administered in combination with a dual nucleoside combination; however, they can also be used as part of a nucleoside-sparing/limiting regimen. PIs should be administered with a boosting agent, either <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>. They can be used for patients who are treatment-naïve, and are often the preferred agent for patients failing their initial antiretroviral therapy (ART) regimen. (See <a class="local">'Pharmacokinetic boosting'</a> below and  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a> and  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Eligibility for two-drug regimens'</a>.)</p><p>Although boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> and boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> are effective as initial therapy in combination with a nucleoside backbone, boosted darunavir is generally preferred since darunavir appears to be better tolerated than atazanavir [<a href="#rid12">12,128,129</a>]. Ritonavir-boosted darunavir, ritonavir-boosted atazanavir, or <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> given with <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> were compared in a randomized study of 1809 ART-naïve patients [<a href="#rid125">125</a>]. There was a 9 percent higher incidence of treatment discontinuation in patients who received boosted atazanavir compared with boosted darunavir (97.5% CI 5.5 to 12.9 percent). This difference was due in large part to clinical jaundice and hyperbilirubinemia associated with atazanavir. </p><p class="headingAnchor" id="H129992652"><span class="h2">PI class characteristics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Protease inhibitors (PIs) competitively inhibit the cleavage of the Gag-Pol polyproteins in HIV-infected cells, which is a crucial step in the viral maturation process, thereby resulting in the production of immature virions that are not infectious. (See <a class="local">'Overview of HIV replication'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> – PIs are active against HIV-1 and HIV-2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – PIs have a relatively high genetic barrier to resistance compared with non-nucleoside reverse transcriptase inhibitors (NNRTIs) and the integrase inhibitors (INSTIs) <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> and <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>. The development of resistance to pharmacologically boosted PIs in previously antiretroviral-naïve individuals is uncommon, even with less than optimal adherence [<a href="#rid130">130</a>]. In clinical trials evaluating the frequency of PI resistance in patients with virologic failure on their initial ART regimen, protease resistance developed in 0 of 76 cases with lopinavir/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, 0 of 140 cases with <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>/ritonavir, and 0 of 46 cases with <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>/ritonavir. Thus, protease inhibitor-based regimens are a good choice for patients in whom adherence is a concern. (See  <a class="medical medical_review" href="/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing", section on 'Protease inhibitors'</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Patients without drug-resistant virus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – There are several side effects that appear to be PI class effects while others are agent-specific. Some of the class side effects are insulin resistance, hyperglycemia, diabetes, hyperlipidemia, lipodystrophy, hepatotoxicity, bleeding in patients with hemophilia, and PR interval prolongation [<a href="#rid131">131-133</a>]. Adverse reactions can also be a result of drug interactions with other hepatically metabolized drugs [<a href="#rid131">131,134</a>]. Specific adverse reactions related to the commonly used agents are described below. (See <a class="local">'Darunavir'</a> below and <a class="local">'Atazanavir'</a> below and <a class="local">'Other protease inhibitors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – It is important to carefully check for potential drug interactions between the PI being considered and other concomitant medications [<a href="#rid135">135</a>]. Under-recognition of these interactions may result in loss of therapeutic effect or excess toxicity. Some studies have demonstrated that unsuspected drug-drug interactions were more common among HIV-infected patients taking PIs compared with those taking antiretroviral medications within other drug classes [<a href="#rid135">135</a>]. Mechanistically, most drug interactions with PIs arise from the pharmacological boosting agents. (See <a class="local">'Pharmacokinetic boosting'</a> below.)</p><p></p><p class="bulletIndent1">For detailed drug interaction information, see the United States Department of Health and Human Services (DHHS) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fadult-and-adolescent-arv%2Fdrug-interactions-between-protease-inhibitors-and-other-drugs%3Fview%3Dfull&amp;token=AiuHD9G3GknBwD4ztqBs9%2BkyCXEvj589yJpcYYNLSyhUen5uD67H94K74AXvkPgsQcKlj3y08s7zfmS39Ubs1VkkGUxUwgJxhZwpFG0SHmhW5gL08p4SA09GDGvp8fqgkPE5NWdT73Q4w0%2BFFd7F2q8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=13978">Antiretroviral Guidelines for Adults and Adolescents</a> (tables 17, 18, and 19) and the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate.</p><p></p><p class="headingAnchor" id="H2209594670"><span class="h2">Specific agents (listed alphabetically)</span></p><p class="headingAnchor" id="H1469476068"><span class="h3">Atazanavir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">Atazanavir</a> should be administered as atazanavir 300 mg once daily plus <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> 100 mg once daily or atazanavir 300 mg once daily plus <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> 150 mg once daily. Atazanavir and cobicistat are coformulated as a single tablet  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). When atazanavir is administered with cobicistat, it should be avoided in patients with an eGFR &lt;70 mL/min/1.73 m<sup>2 </sup>if tenofovir<sup> </sup>disoproxil fumarate-emtricitabine is used as the nucleoside combination. Although the US Food and Drug Administration (FDA) has approved unboosted atazanavir at 400 mg (two 200 mg capsules) once a day, unboosted atazanavir is <strong>not</strong> recommended except in select situations [<a href="#rid12">12,63</a>].</p><p><a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">Atazanavir</a> has the advantage of better gastrointestinal tolerance than most other PIs, once-daily dosing, and good potency. Atazanavir is not associated with the development of insulin resistance when compared with some other PIs such as <a class="drug drug_general" data-topicid="9982" href="/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a>. Lipid profiles show mild increases in cholesterol and triglycerides that are mainly related to <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> [<a href="#rid136">136</a>].</p><p>Disadvantages with <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> include the need for gastric acid and food for optimal absorption; thus, concomitant use of drugs that alter stomach pH (eg, proton pump inhibitors) may impair absorption of the drug. Atazanavir should <strong>not</strong> be used in patients who require a proton pump inhibitor dose equivalent to &gt;20 mg <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> per day. </p><p><a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">Atazanavir</a> has been associated with the development of renal stones and kidney injury (eg, proximal tubular dysfunction, interstitial nephritis, and acute and chronic kidney injury) [<a href="#rid34">34,137-142</a>]. (See  <a class="medical medical_review" href="/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV", section on 'Causes of AKI in patients with HIV'</a>.)</p><p>Adverse reactions also include an increase in the indirect serum bilirubin concentration, which is benign but may cause jaundice. However, in antiretroviral-naïve persons with low cardiovascular risk, the hyperbilirubinemia associated with <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> plus <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> may be responsible for slower progression of carotid artery intima-media thickening compared with those who received <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> boosted with ritonavir [<a href="#rid143">143</a>]. In addition, unlike other PIs, atazanavir is not associated with an increased risk of cardiovascular disease [<a href="#rid144">144-146</a>]. (See  <a class="medical medical_review" href="/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>.)</p><p class="headingAnchor" id="H1322359503"><span class="h3">Darunavir</span><span class="headingEndMark"> — </span>Dosing of <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> for treatment-naïve patients is 800 mg once daily plus <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> 100 mg once daily or darunavir 800 mg once daily plus <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> 150 mg once daily. Darunavir is available in two single coformulated tablets, <a class="drug drug_general" data-topicid="98581" href="/d/drug information/98581.html" rel="external">darunavir-cobicistat</a> and <a class="drug drug_general" data-topicid="118518" href="/d/drug information/118518.html" rel="external">darunavir-cobicistat-emtricitabine-tenofovir alafenamide</a>  (<a class="graphic graphic_table graphicRef60927" href="/d/graphic/60927.html" rel="external">table 1</a>). </p><p>For patients with drug-resistant virus, the dose of <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> depends upon which drug resistance mutations are present. </p><p class="bulletIndent1"><span class="glyph">●</span>We administer <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> twice daily (600 mg darunavir plus 100 mg <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>) if any of the following darunavir resistance mutations are present: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, and L89V). <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">Cobicistat</a> should <strong>not </strong>be used as a boosting agent for such patients who require twice-daily dosing of darunavir.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">Darunavir</a> can be given once daily (800 mg darunavir with 100 mg <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or 150 mg <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>) if there are <strong>no</strong> darunavir mutations, even if there is resistance to other agents [<a href="#rid147">147</a>].</p><p></p><p><a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">Darunavir</a> appears to be the best tolerated PI in randomized studies [<a href="#rid125">125,129</a>]. The principal adverse effects associated with darunavir include nausea, diarrhea, increased transaminases, headache, and rash. However, severe reactions can occur, and darunavir should be discontinued in patients who develop a rash associated with fever, transaminase elevations, eosinophilia, and/or systemic symptoms, as well as those who have severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, exanthematous pustulosis) [<a href="#rid148">148-152</a>]. </p><p><a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">Darunavir</a>, whether given with <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>, should <strong>not</strong> be used in patients with severe liver disease, as infrequent cases of drug-induced liver injury have been reported. In addition, we generally avoid administering darunavir to patients with a sulfonamide allergy, especially those with a severe allergy (eg, rash with systemic symptoms, immediate-type allergy, Stevens-Johnson syndrome) since darunavir contains a sulfonamide moiety. Although most patients with a sulfonamide allergy are able to tolerate darunavir (it lacks one or both essential functional groups implicated in sulfonamide antibiotic hypersensitivity), we prefer using a different third drug for such patients if possible, given the availability of multiple effective alternatives.</p><p class="headingAnchor" id="H1322359661"><span class="h3">Other protease inhibitors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lopinavir</strong> – Lopinavir boosted with <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> is not typically recommended because of issues related to potency, toxicity, and convenience [<a href="#rid12">12,128,129</a>]. However, when it is used, a tenofovir-containing nucleoside reverse transcriptase inhibitor (NRTI) combination is preferred.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9982" href="/d/drug information/9982.html" rel="external">Lopinavir-ritonavir</a> can also be given with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> alone for patients who are unable to tolerate a tenofovir or abacavir-containing backbone [<a href="#rid12">12</a>]. In a randomized study of 426 patients, individuals received lopinavir-ritonavir in combination with lamivudine (dual therapy) or <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> (triple therapy). After 48 weeks of treatment, the number of patients who achieved a viral load &lt;50 copies/mL was similar between the two groups (88 versus 83 percent) [<a href="#rid153">153</a>]. However, a nucleoside-limiting regimen such as lopinavir-ritonavir plus lamivudine may not be suitable for all patients. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Use of two-drug regimens in select patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PIs rarely used</strong> – Several older PIs that were commonly used are either no longer administered or are rarely used because of poor efficacy and/or toxicity. Such agents include <a class="drug drug_general" data-topicid="8558" href="/d/drug information/8558.html" rel="external">indinavir</a>, <a class="drug drug_general" data-topicid="8634" href="/d/drug information/8634.html" rel="external">fosamprenavir</a>, <a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">nelfinavir</a>, <a class="drug drug_general" data-topicid="9877" href="/d/drug information/9877.html" rel="external">saquinavir</a>, and <a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">tipranavir</a>. As an example, although tipranavir is active against strains of HIV that are resistant to other protease inhibitors, it is avoided when possible since it has high rates of hepatotoxicity and has been associated with intracranial hemorrhage [<a href="#rid154">154-157</a>]. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Protease inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H4103970782"><span class="h1">POST-ATTACHMENT INHIBITOR</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="117178" href="/d/drug information/117178.html" rel="external">Ibalizumab</a> is a monoclonal antibody that is given as an intravenous infusion every two weeks and binds the CD4 molecule in such a way that it does not block viral attachment, but does block entry [<a href="#rid158">158</a>]. It is indicated for the treatment of heavily antiretroviral-experienced HIV-1-infected adults with multidrug-resistant virus who are failing their current regimen. It should be used as part of a regimen with other potentially active agents whenever possible. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'If a fully active PI is NOT available'</a>.)</p><p class="headingAnchor" id="H2987197922"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1589709135"><span class="h2">Pharmacokinetic boosting</span><span class="headingEndMark"> — </span>Most protease inhibitors (PIs), as well as the integrase inhibitor <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, are administered in combination with another agent (eg, low-dose <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>) to increase trough plasma drug concentrations, increase drug half-lives, and increase maximum plasma concentrations (C<sub>MAX</sub>). This improves the potency of the antiviral agent and enables lower and less frequent dosing of the parent drug, thereby decreasing pill burden. </p><p>For PIs, pharmacokinetic boosting is done in combination with <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> or low-dose <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>. Although ritonavir is also a PI, it is not used as an antiviral agent when administered at a low dose but rather as a boosting agent for other PIs. Both cobicistat and ritonavir inhibit the hepatic microsomal enzyme CYP (450) 3A4, a characteristic used to "boost" the concentration of the coadministered PI.</p><p><a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">Ritonavir</a> boosting is required for <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> and lopinavir, and is preferred for <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>. As a boosting agent for darunavir and atazanavir, ritonavir is dosed as 100 mg daily; for lopinavir, ritonavir is dosed at 200 mg per day. Ritonavir is available as a tablet, gel cap, and oral solution. Tablets and oral solution do not require refrigeration. The gel capsules should be refrigerated but may be left at room temperature (77°F) for up to 30 days. Full-dose ritonavir (600 mg twice daily) is never used to treat HIV infection because of significant adverse effects at this dose. The major drawbacks of using ritonavir boosting are related to adverse drug interactions, an increased risk of gastrointestinal intolerance, and hyperlipidemia. All of these adverse effects are dose related. </p><p><a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">Cobicistat</a> is chemically similar to <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, but has no antiviral activity. Overall, it is well tolerated, but it has been associated with modest increases in serum creatinine (it inhibits tubular secretion of creatinine), and has gastrointestinal toxicity, lipid changes, and drug interactions comparable with ritonavir. It is also used to boost the integrase inhibitor, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, and the protease inhibitors, <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> and <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>. Coformulated tablets of cobicistat with these agents are available. Cobicistat-boosted regimens should not be used in females of childbearing age who are not committed to effective birth control and in pregnant females due to decreased drug levels during pregnancy. (See  <a class="medical medical_review" href="/d/html/3753.html" rel="external">"HIV and women", section on 'Selection of antiretroviral regimens'</a>.) </p><p class="headingAnchor" id="H4008459867"><span class="h2">Patients who have trouble swallowing tablets</span><span class="headingEndMark"> — </span>Certain patients may have trouble taking combination regimens if they have difficulty swallowing due to other comorbidities, such as candidal esophagitis, or more permanent disabilities, such as stroke. Fortunately, many antiretroviral medications are available as liquid preparations; for other medications, there are methods for dissolving or crushing tablets without losing drug potency [<a href="#rid159">159,160</a>]. The milligram dosing of a liquid preparation may differ from the milligram dose of a tablet formulation, so a direct conversion should not be expected. In addition, some chewable, powder, and liquid formulations are not approved for or conducive to administration to adults. Antiretroviral formulations that can be used for patients who have trouble swallowing pills are described in the table  (<a class="graphic graphic_table graphicRef71499" href="/d/graphic/71499.html" rel="external">table 3</a>). Injectable therapy (eg, long-acting <a class="drug drug_general" data-topicid="130321" href="/d/drug information/130321.html" rel="external">cabotegravir-rilpivirine</a>) may also be an option for selected patients. (See <a class="local">'Cabotegravir'</a> above and  <a class="medical medical_review" href="/d/html/138435.html" rel="external">"Use of long-acting cabotegravir-rilpivirine in people with HIV"</a>.)</p><p class="headingAnchor" id="H2838647831"><span class="h2">Timing of doses for patients on hemodialysis</span><span class="headingEndMark"> — </span>For patients undergoing hemodialysis, we schedule medications so that at least one of the daily ART doses is taken soon after dialysis on dialysis days. As an example, <a class="drug drug_general" data-topicid="116731" href="/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>, <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a>, and <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> specifically should be taken after dialysis on dialysis days [<a href="#rid12">12,161</a>]. Although some antiretroviral agents are probably not dialyzed, the logic behind dosing after dialysis is to guarantee therapeutic plasma concentrations in case dialysis removes some of the drug or an important metabolite. </p><p>More detailed information on the use of specific antiretroviral agents in the setting of dialysis can be found in the Lexicomp drug monographs included with UpToDate and in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fhiv-clinical-guidelines-adult-and-adolescent-arv%2Fdrug-interactions-insti%3Fview%3Dfull&amp;token=M8TWe2LsL5M20fkkeDhxMAg1Ox4tbcbKl8nAYmozqhbLwd8k30UEVCWg35YnAFlg2UAJWMYhKqU1hRVG%2FsQNfpZ1Jahs1I0P0A7AQ1aFa78%2BlFTd0iDUIQjLgX76ay64skkKpjeb2e3cD1Ie3WNBgA%3D%3D&amp;TOPIC_ID=13978">DHHS guidelines</a> [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1957822343"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111624.html" rel="external">"Society guideline links: HIV treatment in nonpregnant adults and adolescents"</a>.)</p><p class="headingAnchor" id="H87047650"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of HIV replication</strong> – The life cycle of HIV can be broken down into 6 steps: (1) entry (binding and fusion), (2) reverse transcription, (3) integration, (4) replication (transcription and translation), (5) assembly, and (6) budding and maturation. The identification and understanding of these processes have provided the basis for antiretroviral agents used to treat HIV. (See <a class="local">'Overview of HIV replication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nucleoside reverse transcriptase inhibitors (NRTIs)</strong> – Nucleoside reverse transcriptase inhibitors (NRTIs) are often referred to as the "backbone" of antiretroviral therapy (ART) regimens and are usually given in pairs. The commonly used combinations are available as coformulations (<a class="drug drug_general" data-topicid="107645" href="/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a>, <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a>, <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a>). (See <a class="local">'Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</strong> – The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are typically administered with an NRTI combination. For treatment-naïve patients, options include <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, and <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a>. <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">Etravirine</a> is generally used for individuals with evidence of drug-resistant virus. (See <a class="local">'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Integrase strand transfer inhibitors</strong> – Regimens using integrase strand transfer inhibitors (INSTIs; eg, bictegravir, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, and <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>) are effective and well tolerated. In many countries, including the United States, INSTIs are considered the preferred third agent for treatment-naïve individuals in combination with two nucleoside analogues. In addition, a once-monthly, injectable regimen (<a class="drug drug_general" data-topicid="130321" href="/d/drug information/130321.html" rel="external">cabotegravir-rilpivirine</a>) is available as switch therapy for treatment-experienced patients who are virologically suppressed on an oral regimen. (See <a class="local">'Integrase strand transfer inhibitors (INSTIs)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protease inhibitors</strong> – Protease inhibitors (PIs) are typically administered with an NRTI combination; however, they can also be used as part of a nucleoside-sparing/limiting regimen. PIs should be administered with a boosting agent such as <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>. They can be used for patients who are treatment-naïve, and are often the preferred agent for patients failing their initial ART regimen. (See <a class="local">'Protease inhibitors (PIs)'</a> above and <a class="local">'Pharmacokinetic boosting'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – There are several antiretroviral agents available for treatment of persons with multidrug-resistant HIV that are not included in the classes above. These include <a class="drug drug_general" data-topicid="140392" href="/d/drug information/140392.html" rel="external">lenacapavir</a> (capsid inhibitor), <a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">fostemsavir</a> (attachment inhibitor), and <a class="drug drug_general" data-topicid="117178" href="/d/drug information/117178.html" rel="external">ibalizumab</a> (post-attachment inhibitor). (See <a class="local">'Capsid inhibitors'</a> above and <a class="local">'Attachment inhibitors'</a> above and <a class="local">'Post-attachment inhibitor'</a> above.)</p><p></p><p class="bulletIndent1">Other antiretroviral agents, such as <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a> (a CCR5 inhibitor) and <a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">enfuvirtide</a> (a fusion inhibitor), are also available; however, they are not commonly used for the treatment of HIV. (See <a class="local">'Entry inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who have trouble swallowing pills</strong> – Certain patients may have trouble taking combination regimens if they have difficulty swallowing due to other comorbidities, such as candidal esophagitis, or more permanent disabilities, such as stroke. For such patients, alternative antiretroviral agents may be available  (<a class="graphic graphic_table graphicRef71499" href="/d/graphic/71499.html" rel="external">table 3</a>). (See <a class="local">'Patients who have trouble swallowing tablets'</a> above.)</p><p></p><p class="headingAnchor" id="H2518115150"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Amy Graziani, PharmD, and Charles Hicks, MD, who contributed to an earlier version of this topic review.</p><p>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 2020; 584:614.</a></li><li class="breakAll">United States FDA. FDA approves new HIV drug for adults with limited treatment options. https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-drug-adults-limited-treatment-options (Accessed on January 12, 2023).</li><li><a class="nounderline abstract_t">Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med 2022; 386:1793.</a></li><li class="breakAll">US Food and Drug Administration. FDA Approves New HIV Treatment for Patients With Limited Treatment Options https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options (Accessed on August 06, 2020).</li><li><a class="nounderline abstract_t">Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med 2020; 382:1232.</a></li><li class="breakAll">Lataillade JM et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study). 10th International AIDS Society Conference on HIV Science, Mexico City, abstract MOAB0102, 2019. https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25327 (Accessed on September 25, 2020).</li><li><a class="nounderline abstract_t">Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159.</a></li><li><a class="nounderline abstract_t">Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685.</a></li><li><a class="nounderline abstract_t">Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33:1931.</a></li><li><a class="nounderline abstract_t">Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33:1914.</a></li><li><a class="nounderline abstract_t">Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (Accessed on March 03, 2021).</li><li><a class="nounderline abstract_t">Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191.</a></li><li><a class="nounderline abstract_t">Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230.</a></li><li><a class="nounderline abstract_t">Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.</a></li><li><a class="nounderline abstract_t">D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.</a></li><li><a class="nounderline abstract_t">Marcus JL, Neugebauer RS, Leyden WA, et al. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr 2016; 71:413.</a></li><li><a class="nounderline abstract_t">Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013; 56:1637.</a></li><li><a class="nounderline abstract_t">Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57:245.</a></li><li><a class="nounderline abstract_t">Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289.</a></li><li><a class="nounderline abstract_t">Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929.</a></li><li><a class="nounderline abstract_t">Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807.</a></li><li><a class="nounderline abstract_t">Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547.</a></li><li><a class="nounderline abstract_t">Bansi L, Sabin C, Gilson R, et al. Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis 2009; 200:710.</a></li><li><a class="nounderline abstract_t">Holdich T, Shiveley LA, Sawyer J. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007; 51:2943.</a></li><li class="breakAll">GlaxoSmithKline. Epivir (lamivudine) tablets and oral solution. Research Triangle Park, NC. 2008.</li><li><a class="nounderline abstract_t">Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.</a></li><li><a class="nounderline abstract_t">Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013; 63:449.</a></li><li><a class="nounderline abstract_t">Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.</a></li><li><a class="nounderline abstract_t">Schafer JJ, Sassa KN, O'Connor JR, et al. Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis 2019; 6:ofz414.</a></li><li><a class="nounderline abstract_t">Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection 2019; 47:95.</a></li><li><a class="nounderline abstract_t">Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis 2020; 71:1379.</a></li><li><a class="nounderline abstract_t">Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283.</a></li><li><a class="nounderline abstract_t">Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e96.</a></li><li><a class="nounderline abstract_t">Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013; 24:1519.</a></li><li><a class="nounderline abstract_t">Huang JS, Hughes MD, Riddler SA, et al. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 2013; 14:224.</a></li><li><a class="nounderline abstract_t">Yin MT, Overton ET. Increasing clarity on bone loss associated with antiretroviral initiation. J Infect Dis 2011; 203:1705.</a></li><li><a class="nounderline abstract_t">McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791.</a></li><li><a class="nounderline abstract_t">Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74.</a></li><li><a class="nounderline abstract_t">Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535.</a></li><li><a class="nounderline abstract_t">Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49.</a></li><li><a class="nounderline abstract_t">Flynn PM, Rodman J, Lindsey JC, et al. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother 2007; 51:3516.</a></li><li><a class="nounderline abstract_t">Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus. Pharmacotherapy 2004; 24:307.</a></li><li><a class="nounderline abstract_t">Berenguer J, González J, Ribera E, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 2008; 47:1083.</a></li><li><a class="nounderline abstract_t">Grobler JA, Dornadula G, Rice MR, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem 2007; 282:8005.</a></li><li><a class="nounderline abstract_t">Zdanowicz MM. The pharmacology of HIV drug resistance. Am J Pharm Educ 2006; 70:100.</a></li><li><a class="nounderline abstract_t">Anta L, Llibre JM, Poveda E, et al. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 2013; 27:81.</a></li><li><a class="nounderline abstract_t">Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008; 47:421.</a></li><li class="breakAll">Kilkaire B, Walker S, Khoo S, et al. Plasma levels of nevirapine following interruption of ZDV/3Tc/nvp in African adults within the DART trial. Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada. Abstract WEAB0201.</li><li><a class="nounderline abstract_t">Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis 2019; 68:535.</a></li><li><a class="nounderline abstract_t">Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV 2018; 5:e211.</a></li><li><a class="nounderline abstract_t">Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304.</a></li><li><a class="nounderline abstract_t">van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.</a></li><li><a class="nounderline abstract_t">Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011.</a></li><li><a class="nounderline abstract_t">Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865.</a></li><li><a class="nounderline abstract_t">Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 2001; 15:1679.</a></li><li class="breakAll">Montaner JS, Saag MS, Barylski C, Siemon-Hryczyk P. FOCUS study: saquinavir QD reigmen versus efavirenz QD regimen 48 week analysis in HIV infected patients. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego. (Abstract).</li><li class="breakAll">Bartlett JA, Johnson J, Herrera G, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) preliminary 48 week results. In 14th International AIDS Conference; 2002; Barcelona. (Abstract).</li><li><a class="nounderline abstract_t">Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008; 197:1006.</a></li><li><a class="nounderline abstract_t">Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439.</a></li><li><a class="nounderline abstract_t">Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63:77.</a></li><li><a class="nounderline abstract_t">Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796.</a></li><li><a class="nounderline abstract_t">Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023; 329:63.</a></li><li><a class="nounderline abstract_t">Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006; 7:544.</a></li><li><a class="nounderline abstract_t">Leutscher PD, Stecher C, Storgaard M, Larsen CS. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis 2013; 45:645.</a></li><li><a class="nounderline abstract_t">Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014; 161:1.</a></li><li><a class="nounderline abstract_t">Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714.</a></li><li><a class="nounderline abstract_t">Mollan KR, Tierney C, Hellwege JN, et al. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. J Infect Dis 2017; 216:554.</a></li><li><a class="nounderline abstract_t">Chang JL, Tsai AC, Musinguzi N, et al. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Ann Intern Med 2018; 169:146.</a></li><li><a class="nounderline abstract_t">ENCORE1 Study Group, Carey D, Puls R, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; 15:793.</a></li><li><a class="nounderline abstract_t">Lamorde M, Wang X, Neary M, et al. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. Clin Infect Dis 2018; 67:785.</a></li><li><a class="nounderline abstract_t">NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med 2019; 381:816.</a></li><li><a class="nounderline abstract_t">Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009; 48:1123.</a></li><li><a class="nounderline abstract_t">Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825.</a></li><li><a class="nounderline abstract_t">Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl 1:S21.</a></li><li><a class="nounderline abstract_t">Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009; 23:1689.</a></li><li><a class="nounderline abstract_t">Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis 2011; 53:341.</a></li><li><a class="nounderline abstract_t">Aaron E, Kempf MC, Criniti S, et al. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One 2010; 5:e12617.</a></li><li><a class="nounderline abstract_t">van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463.</a></li><li><a class="nounderline abstract_t">Carr DF, Chaponda M, Jorgensen AL, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis 2013; 56:1330.</a></li><li><a class="nounderline abstract_t">Dodi F, Alessandrini A, Camera M, et al. Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports. AIDS 2002; 16:1197.</a></li><li><a class="nounderline abstract_t">Zhang C, Wang W, Zhou M, et al. The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted. J Acquir Immune Defic Syndr 2013; 62:540.</a></li><li class="breakAll">Product labeling. Edurant (rilpivirine). Tibotec, May 2015.</li><li><a class="nounderline abstract_t">Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24:55.</a></li><li><a class="nounderline abstract_t">Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 2014; 28:989.</a></li><li><a class="nounderline abstract_t">Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults. Clin Ther 2010; 32:328.</a></li><li><a class="nounderline abstract_t">Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.</a></li><li><a class="nounderline abstract_t">Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.</a></li><li><a class="nounderline abstract_t">Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 2013; 27:939.</a></li><li><a class="nounderline abstract_t">Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646.</a></li><li><a class="nounderline abstract_t">Hazuda DJ, Felock PJ, Hastings JC, et al. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J Virol 1997; 71:7005.</a></li><li><a class="nounderline abstract_t">Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74:11191.</a></li><li><a class="nounderline abstract_t">Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004; 78:5045.</a></li><li><a class="nounderline abstract_t">Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4:236.</a></li><li><a class="nounderline abstract_t">Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010; 44:145.</a></li><li><a class="nounderline abstract_t">Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 2010; 65:2485.</a></li><li><a class="nounderline abstract_t">Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204.</a></li><li><a class="nounderline abstract_t">Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012; 56:2873.</a></li><li class="breakAll">Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc; August 2012</li><li><a class="nounderline abstract_t">Llibre JM, Pulido F, García F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev 2015; 17:56.</a></li><li><a class="nounderline abstract_t">Gutiérrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev 2014; 16:199.</a></li><li><a class="nounderline abstract_t">Norwood J, Turner M, Bofill C, et al. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr 2017; 76:527.</a></li><li><a class="nounderline abstract_t">Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med 2019; 381:803.</a></li><li><a class="nounderline abstract_t">Bourgi K, Rebeiro PF, Turner M, et al. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis 2020; 70:1267.</a></li><li><a class="nounderline abstract_t">Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18:56.</a></li><li><a class="nounderline abstract_t">Fettiplace A, Stainsby C, Winston A, et al. Psychiatric Symptoms in Patients Receiving Dolutegravir. J Acquir Immune Defic Syndr 2017; 74:423.</a></li><li><a class="nounderline abstract_t">Osterholzer DA, Goldman M. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis 2014; 59:265.</a></li><li><a class="nounderline abstract_t">Oliveira M, Mesplède T, Quashie PK, et al. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28:813.</a></li><li><a class="nounderline abstract_t">van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111.</a></li><li><a class="nounderline abstract_t">Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207:740.</a></li><li class="breakAll">Nichols G, et al. Phase 3 assessment of dolutegravir (DTG) 50mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled. 7th IAS, Kuala Lumpur, 2013, Abstract TULBPE19
</li><li><a class="nounderline abstract_t">Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735.</a></li><li><a class="nounderline abstract_t">Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27:1771.</a></li><li><a class="nounderline abstract_t">Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013; 52:981.</a></li><li class="breakAll">Gervasoni C, Riva A, Capetti A, et al. Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat. Presented at CROI 2017. Seattle, Washington. Abstract #410.</li><li><a class="nounderline abstract_t">Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222.</a></li><li><a class="nounderline abstract_t">DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429.</a></li><li><a class="nounderline abstract_t">Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016; 16:43.</a></li><li><a class="nounderline abstract_t">Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355.</a></li><li><a class="nounderline abstract_t">Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.</a></li><li><a class="nounderline abstract_t">Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50:605.</a></li><li><a class="nounderline abstract_t">Perry ME, Almaani N, Desai N, et al. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety. Int J STD AIDS 2013; 24:639.</a></li><li><a class="nounderline abstract_t">Lee FJ, Amin J, Bloch M, et al. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr 2013; 62:525.</a></li><li><a class="nounderline abstract_t">Thomas M, Hopkins C, Duffy E, et al. Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. Clin Infect Dis 2017; 64:1198.</a></li><li><a class="nounderline abstract_t">Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161:461.</a></li><li><a class="nounderline abstract_t">Barau C, Delaugerre C, Braun J, et al. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother 2010; 54:937.</a></li><li><a class="nounderline abstract_t">Yilmaz A, Gisslén M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4:e6877.</a></li><li><a class="nounderline abstract_t">Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646.</a></li><li><a class="nounderline abstract_t">Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679.</a></li><li><a class="nounderline abstract_t">Gardner EM, Hullsiek KH, Telzak EE, et al. Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS 2010; 24:395.</a></li><li><a class="nounderline abstract_t">Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127:948.</a></li><li><a class="nounderline abstract_t">Tsiodras S, Perelas A, Wanke C, Mantzoros CS. The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications. J Infect 2010; 61:101.</a></li><li><a class="nounderline abstract_t">Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25:367.</a></li><li><a class="nounderline abstract_t">Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127:947.</a></li><li><a class="nounderline abstract_t">Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1419.</a></li><li><a class="nounderline abstract_t">Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010; 24:2019.</a></li><li><a class="nounderline abstract_t">Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207:1359.</a></li><li><a class="nounderline abstract_t">Ryom L, Mocroft A, Lundgren J. HIV therapies and the kidney: some good, some not so good? Curr HIV/AIDS Rep 2012; 9:111.</a></li><li><a class="nounderline abstract_t">Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41.</a></li><li><a class="nounderline abstract_t">Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041.</a></li><li><a class="nounderline abstract_t">Ribaudo HJ, Daar ES, Tierney C, et al. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis 2013; 207:420.</a></li><li><a class="nounderline abstract_t">Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262.</a></li><li><a class="nounderline abstract_t">Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015; 29:1775.</a></li><li><a class="nounderline abstract_t">Monforte Ad, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013; 27:407.</a></li><li><a class="nounderline abstract_t">LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS 2017; 31:2095.</a></li><li class="breakAll">Ryom L et al. Association between cardiovascular disease and contemporarily used protease inhibitors. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, 2017.</li><li><a class="nounderline abstract_t">Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929.</a></li><li><a class="nounderline abstract_t">Nishijima T, Gatanaga H, Teruya K, et al. Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. J Infect Chemother 2014; 20:285.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021976s034,202895s011lbl.pdf (Accessed on April 29, 2014).</li><li><a class="nounderline abstract_t">Vispo E. Warning on hepatotoxicity of darunavir. AIDS Rev 2008; 10:63.</a></li><li><a class="nounderline abstract_t">Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349.</a></li><li><a class="nounderline abstract_t">Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol 2010; 63:549.</a></li><li><a class="nounderline abstract_t">Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14:572.</a></li><li><a class="nounderline abstract_t">Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008; 47:429.</a></li><li><a class="nounderline abstract_t">Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007; 45:761.</a></li><li><a class="nounderline abstract_t">Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347.</a></li><li class="breakAll">Cooper D, Zajdenverg R, Ruxrungtham K, et al. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33 (Abstract PL13.4]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV infection 2006.</li><li><a class="nounderline abstract_t">Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med 2018; 379:645.</a></li><li><a class="nounderline abstract_t">Huesgen E, DeSear KE, Egelund EF, et al. A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios. Pharmacotherapy 2016; 36:1145.</a></li><li><a class="nounderline abstract_t">Fulco PP. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. Am J Health Syst Pharm 2020; 77:509.</a></li><li class="breakAll">US Food and Drug Administration. Biktarvy: prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210251s007lbl.pdf (Accessed on March 03, 2021).</li></ol></div><div id="topicVersionRevision">Topic 13978 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32612233" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical targeting of HIV capsid protein with a long-acting small molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32612233" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical targeting of HIV capsid protein with a long-acting small molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544387" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544387" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32212519" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32212519" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523272" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10929917" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692306" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692304" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668455" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668455" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917892" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952143" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753925" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387667" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26536316" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362296" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21499115" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21516027" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427402" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24195548" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542866" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635022" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Virological response to initial antiretroviral regimens containing abacavir or tenofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242147" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242147" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421366" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807155" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890673" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31660372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30269210" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31606734" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355343" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234519" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052632" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24144899" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606527" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Increasing clarity on bone loss associated with antiretroviral initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606537" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971715" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17057609" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431394" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664328" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15040643" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18781872" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17172472" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149429" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The pharmacology of HIV drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22842995" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558886" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558886" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184165" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29592840" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668456" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15094269" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247553" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601505" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11546943" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11546943" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11546943" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419537" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748591" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23412015" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19647866" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36454551" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105514" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23427878" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24979445" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287792" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28931220" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946683" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877963" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30124823" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339676" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19275497" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15717255" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14562855" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487907" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810746" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20838641" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764851" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362284" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12004287" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288032" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288032" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926964" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508782" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206790" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763936" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763935" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23211772" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10649997" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261430" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11070016" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Repair of gaps in retroviral DNA integration intermediates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113886" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729361" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Integrase inhibitors to treat HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040702" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Integrase inhibitors: a novel class of antiretroviral agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20852268" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Integrase inhibitors in the treatment of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459813" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : HIV-1 integrase inhibitor resistance and its clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22450969" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22450969" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472016" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Genetic barrier to resistance for dolutegravir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25350530" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28825943" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339677" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31100116" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27860104" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27984559" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Psychiatric Symptoms in Patients Receiving Dolutegravir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723281" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463394" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018760" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23225901" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23225901" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23306000" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807273" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824675" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824675" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24698485" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748590" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538525" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650513" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650512" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Raltegravir with optimized background therapy for resistant HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20085491" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23970584" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23274936" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369189" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25285539" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995925" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721718" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18722869" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487905" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20099399" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382376" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : New-onset diabetes mellitus associated with use of protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547180" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150558" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382374" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Severe diabetes associated with protease inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20380564" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20613461" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23382571" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370968" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : HIV therapies and the kidney: some good, some not so good?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17148966" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20192725" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23148286" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820542" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372383" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23291539" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692532" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692532" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346512" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507978" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507978" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18432296" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Warning on hepatotoxicity of darunavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855799" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846563" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24783988" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176328" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712762" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Tipranavir: a new option for the treatment of drug-resistant HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051504" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051504" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30110589" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27636237" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32207818" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
